Featured Research

from universities, journals, and other organizations

"Super" Aspirin And Clot Buster May Prevent Surgery

Date:
June 2, 1999
Source:
American Heart Association
Summary:
Two clot-thinning drugs may be better than one for treating heart attacks, according to results of new study that appears in today's issue of Circulation: Journal of the American Heart Association.

Dallas, June 1 -- Two clot-thinning drugs may be better than one for treating heart attacks, according to results of new study that appears in today's issue of Circulation: Journal of the American Heart Association.

One drug, called a thrombolytic, dissolves blood clots. The second drug, a platelet IIb/IIIa receptor blocker, keeps platelets from clumping and forming the blood clots that can obstruct blood flow and thereby trigger a heart attack or stroke. The platelet blockers, sometimes called "super aspirin" are more potent than aspirin. They are also administered through an intravenous drip or infusion.

According to lead investigator of the study, Elliott Antman, M.D., director of the Coronary Care Unit at Brigham and Women's Hospital, Boston, "The trial tested the hypothesis that the platelet blocker is a potent and safe addition to thrombolytic regimens."

Results of the new study, called the TIMI 14 trial, are so impressive, that researchers say that many individuals with heart attacks who otherwise would require angioplasty or bypass surgery to restore blood flow to the heart may be treated instead with both drugs. Angioplasty involves using a narrow tube with a deflated balloon on its tip that is passed into the narrowed part of the artery. When the balloon is inflated, the blockages or blood clots are pushed aside, allowing blood to flow through. Bypass surgery is an operation that uses blood vessels "borrowed" from another part of the body to go around clogged coronary arteries to reestablish blood flow to the heart.

According to J. Ward Kennedy, M.D., who wrote an accompanying editorial, the investigators have "made a major contribution to the management of acute myocardial infarctions (heart attacks)"-- and identified a therapy, which will likely prove to be equivalent or superior to opening blood vessels with medical procedures such as angioplasty.

The study included 888 individuals who had suffered a heart attack. Patients were treated with one of four therapies; alteplase, alone, abciximab alone or abciximab with reduced doses of alteplase.

Each patient received an angiogram, a visualization of the blood vessels that uses X-rays to determine how quickly the drugs dissolved blood clots in the vessel. The study examined the ability of the drugs to dissolve blood clots within 60 and 90 minutes. The study showed that 72 percent of heart attack victims who received abciximab plus half the standard dose of alteplase achieve optimal blood flow in their arteries within 60 minutes of treatment compared with only 43 percent of patients treated with alteplase alone. Within 90 minutes, 77 percent of patients treated with combination therapy achieved this level of blood flow, compared with 62 percent given alteplase alone.

Clot-buster drugs currently are the standard therapy for treating heart attacks. However, they are not always effective and many individuals develop recurrent blood clots.

"By enhancing the effects of clot-busters, abciximab may improve the treatment for heart attacks, and allow more patients to be treated with drugs rather than angioplasty and surgery," says Antman.


Story Source:

The above story is based on materials provided by American Heart Association. Note: Materials may be edited for content and length.


Cite This Page:

American Heart Association. ""Super" Aspirin And Clot Buster May Prevent Surgery." ScienceDaily. ScienceDaily, 2 June 1999. <www.sciencedaily.com/releases/1999/06/990602072700.htm>.
American Heart Association. (1999, June 2). "Super" Aspirin And Clot Buster May Prevent Surgery. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/1999/06/990602072700.htm
American Heart Association. ""Super" Aspirin And Clot Buster May Prevent Surgery." ScienceDaily. www.sciencedaily.com/releases/1999/06/990602072700.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins